Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Klotho Neurosciences ( (KLTO) ) has provided an update.
On August 12, 2025, Klotho Neurosciences announced a binding agreement with AAVnerGene Inc. to initiate the manufacturing and development of its KLTO-202 gene therapy candidate using AAVnerGene’s platform technology. This collaboration aims to leverage AAVnerGene’s advanced AAVone and ATHENA technologies to enhance production efficiency, reduce costs, and improve the safety and efficacy of the gene therapy. The partnership marks a significant milestone for Klotho Neurosciences, potentially accelerating the clinical launch of its product candidates with higher purity and lower risk of side effects compared to traditional methods.
More about Klotho Neurosciences
Klotho Neurosciences, Inc. is a biotechnology company focused on developing innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the ‘anti-aging’ human Klotho gene. The company aims to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer’s disease, and Parkinson’s disease. Its portfolio includes proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays.
Average Trading Volume: 43,231,066
Technical Sentiment Signal: Hold
Current Market Cap: $43.85M
See more insights into KLTO stock on TipRanks’ Stock Analysis page.